Taken together, results from this study revealed that SIS3 is an effective therapeutic agent and is capable of targeting Smad3-mediated both T2D and T2DN when it is used earlier in prediabetic db/db mice. The gene discussed is SMAD3; the disease is type 2 diabetes mellitus.